NOVAVAX COVID-19 VACCINE CANDIDATE 89-PERCENT EFFECTIVE IN EARLY STUDY RESULTS

Jan 29, 2021

By Jane Brown

Share on

Another COVID-19 vaccine candidate has emerged.

The makers at Novavax Inc. say it appears about 89 per cent effective overall in early results from a British Study.

Company scientists say it also seems to work, although not quite as well, on the new mutated versions of COVID-19 which originated in the United Kingdom and South Africa.

Lead research nurse Vash Deelchand gives a demonstration of the vaccine trial process as Kate Bingham, Chair of the Government’s Vaccine Taskforce, starts her Novavax trial at the Royal Free Hospital, north London. (Photo by Kirsty O’Connor/PA Images via Getty Images)

The study of the Novavax candidate involving 15,000 people in Britain continues, but an interim analysis finds the vaccine is 96 per cent effective against the original new coronavirus and nearly 86 per cent effective against the new U.K. variant.

Novavax scientists are waiting for additional data before seeking British approval for the vaccine’s use which they expect to have sometime next month.

Zoomer Kids
You Don't Have To Be A Zoomer To Love Zoomer Radio.
Check out what the Kids have to say!
Join Our Fan Club
Coverage Area
Downtown Toronto
96.7FM
Toronto HD
96.3 HD-2
Kingston to Windsor, Parry Sound to Pittsburgh
AM740
ZoomerRadio Logo

Recently Played: